Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A prostaglandin E1 dose-response study in man

B von Heyden1, C F Donatucci, G A Marshall

  • 1Department of Urology, University of California School of Medicine, San Francisco.

The Journal of Urology
|December 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The AlzMatch Pilot Study - Feasibility of Remote Blood Collection of Plasma Biomarkers for Preclinical Alzheimer's Disease Trials.

The journal of prevention of Alzheimer's disease·2024
Same author

Longitudinal Trajectories of the Cognitive Function Index in the A4 Study.

The journal of prevention of Alzheimer's disease·2024
Same author

Longitudinal Evolution of Financial Capacity and Cerebral Tau and Amyloid Burden in Older Adults with Normal Cognition or Mild Cognitive Impairment.

The journal of prevention of Alzheimer's disease..·2024
Same author

Everyday Functioning and Entorhinal and Inferior Temporal Tau Burden in Cognitively Normal Older Adults.

The journal of prevention of Alzheimer's disease·2022
Same author

Subjective Cognitive Decline in a Registry Sample: Relation to Psychiatric History, Loneliness, and Personality.

The journal of prevention of Alzheimer's disease·2022
Same author

Item-Level Investigation of Participant and Study Partner Report on the Cognitive Function Index from the A4 Study Screening Data.

The journal of prevention of Alzheimer's disease·2021
Same journal

On the Memoryless Property in Markov Models for NMIBC Cost-Effectiveness Analysis.

The Journal of urology·2026
Same journal

Multi-institutional Assessment of Performance Metrics for MRI-targeted Transperineal Prostate Biopsy.

The Journal of urology·2026
Same journal

Urinary Supersaturation in a Randomized Trial among Individuals with Recurrent Nephrolithiasis comparing Empiric versus Selective Preventive Therapy: The URINE Trial.

The Journal of urology·2026
Same journal

The FDA Should Allow More BCG Strains into the US Market: How Recent Landmark Trials Expose a Regulatory Paradox.

The Journal of urology·2026
Same journal

Let's Shift the Focus from Death to Life after Fournier's Gangrene.

The Journal of urology·2026
Same journal

Endourology and Nephrolithiasis.

The Journal of urology·2026
See all related articles

Prostaglandin E1 (PGE1) causes erections by relaxing smooth muscles. This study found that increasing PGE1 doses beyond 20 micrograms offered little additional benefit, indicating a receptor-dependent effect for treating impotence.

Area of Science:

  • Urology
  • Pharmacology
  • Reproductive Medicine

Background:

  • Prostaglandin E1 (PGE1) is known to induce erections via smooth muscle relaxation.
  • Its receptor-dependent mechanism suggests a limit to dose-dependent efficacy.

Purpose of the Study:

  • To investigate the dose-response relationship of intracavernous prostaglandin E1 in men with vasculogenic impotence.
  • To determine the optimal dosage of PGE1 for achieving maximal erectile response.

Main Methods:

  • A single-blind, placebo-controlled study involving 16 men with vasculogenic impotence.
  • Intracavernosal injections of increasing PGE1 dosages (2.5 to 20 micrograms and higher).
  • Erection parameters (rigidity, tumescence, duration) monitored in real-time using the RigiScan device for 2 hours.

Related Experiment Videos

Main Results:

  • A nonlinear dose-response curve was observed for all measured erection parameters.
  • A plateau in efficacy was reached at PGE1 doses greater than 20 micrograms.
  • Over 80% of patients achieved maximal erectile response with 20 micrograms or less of PGE1.

Conclusions:

  • Prostaglandin E1's erectile effects are receptor-dependent.
  • Monotherapy with PGE1 for impotence may be optimized at 20 micrograms or less, as higher doses provide minimal additional benefit.